Stevens-Johnson Syndrome Disease

DESCRIPTION
Until recently Stevens-Johnson syndrome (SJS) was considered to be the same as erythema multiforme major, a severe form of erythema multiforme in which more than one mucosal surface was involved. Now it is thought that erythema multiforme spectrum is a single entity. The milder form, also known as erythema multiforme-Hebra, either has no mucous membrane involvement, or may involve one mucous membrane. The more severe form is erythema multiforme major, involving more than one mucus membrane. In both these variants, it is a self limited hypersensitivity reaction, usually to a preceding viral infection, and has an excellent prognosis. SJS is a generalized hypersensitivity reaction, usually to a drug, in which the skin and mucus membrane lesions are early manifestation. It may progress to its more severe form, toxic epidermal necrolysis which has a high morbidity and up to 40% mortality.
  • System(s) affected: Skin/exocrine, Nervous, Cardiovascular, Renal/Urologic, Hemic/Lymphatic/Immunologic
  • Genetics: Possibly associated with HLA-B15
  • Incidence/Prevalence in USA: Difficult to estimate because of confusion with erythema multiforme major, perhaps 0.1/100,000, or less.
  • Predominant age: More common in children and young adults
  • Predominant sex: Males > Females (2:1)
SIGNS AND SYMPTOMS
  • There is usually a preceding illness for which medication was given
  • Sudden onset with rapid progressive pleomorphic rash which includes petechiae, vesicles, bullae
  • The condition is classified as SJS if epidermal detachment affects less than 10% of the skin, as toxic epidermal necrolysis (TEN) if epidermal detachment exceeds 30%, or if it exceeds 10% in the absence of discrete skin lesions. Cases with discrete skin lesions and between 10% and 30% epidermal detachment are in the overlap between SJS and TEN.
  • Vesicles and ulcers on the mucous membranes, especially of the mouth and throat
  • Burning sensation of the skin and sometimes of the mucous membranes
  • Usually no pruritus
  • Fever 39-40°C (102-104°F)
  • Headache
  • Malaise
  • Arthralgias
  • Epistaxis
  • Crusted nares
  • Conjunctivitis
  • Corneal ulcerations
  • Erosive vulvovaginitis or balanitis
  • Cough productive of thick purulent sputum
  • Tachypnea/respiratory distress
  • Albuminuria/hematuria
  • Arrhythmias
  • Pericarditis
  • Congestive heart failure
  • Mental status changes
  • Electrolyte disturbance
  • Seizures
  • Coma
  • Sepsis
CAUSES
  • Often unknown
  • Medications - especially sulfonamides, penicillins, anticonvulsants, salicylates, nonsteroidal anti-inflammatory drugs, methazolamide, carvedilol (3,4)
  • Vaccines - diphtheria/typhoid, bacillus Calmette Guerin (BCG), oral polio vaccine (OPV)
  • Mycoplasma pneumonia virus infection
RISK FACTORS
  • Patients with HIV infection appear to be predisposed to developing SJS in response to their medications
  • Previous history of SJS
  • Male sex
LABORATORY

Culture or serological tests for suspected sources of infection

Drugs that may alter lab results: N/A
Disorders that may alter lab results: N/A

PATHOLOGICAL FINDINGS
Compared with the mainly inflammatory changes in erythema multiforme, necrotic changes predominate in SJS and TEN. There is a cell poor infiltrate in which macrophages and dendrocytes predominate with a strong immunoreactivity for TNF-alpha.
SPECIAL TESTS
None
IMAGING

N/A

DIAGNOSTIC PROCEDURES
Skin biopsy
APPROPRIATE HEALTH CARE

Since this disease can progress quickly, all patients should be admitted. If the sloughed skin exceeds 10% of the body surface, consideration should be given to transferring the patient to a burns unit. Bronchiolitis, adult respiratory distress syndrome or multi-organ damage may require care in an intensive care unit.

GENERAL MEASURES
  • Withdrawal of any suspected medication, and treatment of any underlying disease
  • Meticulous care of damaged skin
  • Reverse isolation when epidermal loss is extensive
  • Maintenance of fluid, electrolyte and protein balance
  • Adequate calorie intake, parenteral nutrition if necessary
  • Oral hygiene with mouthwashes of warm saline, or solution of diphenhydramine, lidocaine, and kaolin suspension
  • Ophthalmological consultation and monitoring for corneal damage
SURGICAL MEASURES

Sterile débridement of areas of extensive epidermal loss. Application of biosynthetic dressings such as Biobrane to denuded areas (13 ) Long term damage to the vulva or vagina or to the cornea or may need surgical repair.

ACTIVITY

Bed rest until clinically stabilized

DIET

As tolerated. Increased fluid intake is recommended. Intravenous nutritional support may be needed.

PATIENT EDUCATION
  • The patient should be kept informed of the progress of the disease, and the treatment options available
  • Recurrences are possible. Etiologic agents should be identified if possible, and avoided indefinitely.
PREVENTION/AVOIDANCE
  • It is rarely possible to anticipate a first attack
  • Avoid reexposure to the presumed cause
POSSIBLE COMPLICATIONS
  • Secondary infections
  • Sepsis
  • Pneumonia
  • Adult respiratory distress syndrome
  • Bronchiolitis obliterans in children
  • Dehydration/electrolyte disturbance
  • Acute tubular necrosis
  • Corneal ulceration or iritis
  • Arrhythmias
  • Death in about 15% of untreated cases of SJS, and up to 40% of TEN
EXPECTED COURSE AND PROGNOSIS
  • Disease may have a rapid onset, or may evolve slowly over 1-2 weeks, with resolution over 4 to 6 weeks
  • There may be scarring of the skin or mucous membranes, especially of the vulva
  • There may be blindness or corneal opacities in 7-20% of patients
  • Risk of recurrence may be as high as 37%
  • Death occurs in 5-15% of patients with SJS, and up to 40% of patients with TEN
ASSOCIATED CONDITIONS
  • Stevens-Johnson syndrome and toxic epidermal necrolysis are associated conditions
  • Mycoplasma pneumonia has been described as a viral precursor
AGE-RELATED FACTORS

Pediatric: Rare under 3 years. More common in children and young adults
Geriatric: TEN has a greater mortality in older patients
Others: N/A

PREGNANCY

Reported as a possible predisposing condition

OTHER NOTES

N/A

ABBREVIATIONS

N/A

Clinical Investigations

ROLE OF HOMOEOPATHY

Copyright © 2025 Selkey. All Rights Reserved.